{
    "guideline_identifier": "PIIS0923753421042800.txt",
    "cancer_focus": {
        "primary_cancer": "Bone Sarcomas",
        "related_syndrome_or_condition": "Li-Fraumeni syndrome, Werner syndrome, Rothmund-Thomson syndrome, Bloom syndrome, hereditary retinoblastoma, multiple osteochondromas, enchondromatosis"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Osteosarcoma: Localized",
            "risk_group": "Age ≤40 years",
            "treatment_plans": [
                {
                    "clinical_context": "Localized extremity osteosarcoma",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Neoadjuvant/adjuvant chemotherapy with MAP regimen (methotrexate, doxorubicin, cisplatin) + surgery",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I A"
                }
            ]
        },
        {
            "staging_criteria": "Osteosarcoma: Localized",
            "risk_group": "Age >40 years",
            "treatment_plans": [
                {
                    "clinical_context": "Localized osteosarcoma in older adults",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Doxorubicin/cisplatin/ifosfamide regimen (avoiding high-dose methotrexate)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level III B"
                }
            ]
        },
        {
            "staging_criteria": "Osteosarcoma: Craniofacial",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Unresectable craniofacial osteosarcoma",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Chemotherapy + radiotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV B"
                }
            ]
        },
        {
            "staging_criteria": "Osteosarcoma: Metastatic",
            "risk_group": "Resectable metastases",
            "treatment_plans": [
                {
                    "clinical_context": "Metastatic osteosarcoma with resectable lesions",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Curative-intent surgical resection of metastases + chemotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level III B"
                }
            ]
        },
        {
            "staging_criteria": "Osteosarcoma: Recurrent",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Recurrent osteosarcoma",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Surgical resection of isolated metastases + second-line chemotherapy (ifosfamide/cyclophosphamide ± etoposide/carboplatin)",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level III B"
                }
            ]
        },
        {
            "staging_criteria": "Ewing Sarcoma: Localized",
            "risk_group": "Standard-risk",
            "treatment_plans": [
                {
                    "clinical_context": "Non-pelvic, small volume tumors with good histologic response",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Interval-compressed VDC/IE chemotherapy (vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "FET-ETS fusions",
                            "status": "Present",
                            "testing_guidance": "Confirm via FISH/RT-PCR for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level I B"
                },
                {
                    "clinical_context": "Local control for resectable tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Surgery preferred over radiotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "FET-ETS fusions",
                            "status": "Present",
                            "testing_guidance": "Confirm via FISH/RT-PCR for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level IV A"
                }
            ]
        },
        {
            "staging_criteria": "Ewing Sarcoma: Localized",
            "risk_group": "High-risk",
            "treatment_plans": [
                {
                    "clinical_context": "Pelvic/vertebral tumors, large volume (>200mL), poor histologic response",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "High-dose chemotherapy with stem cell rescue (BuMel protocol)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "FET-ETS fusions",
                            "status": "Present",
                            "testing_guidance": "Confirm via FISH/RT-PCR for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level I"
                },
                {
                    "clinical_context": "Adjuvant therapy after resection",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Postoperative radiotherapy for poor response, large tumors, or pelvic sites",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "FET-ETS fusions",
                            "status": "Present",
                            "testing_guidance": "Confirm via FISH/RT-PCR for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level II B"
                }
            ]
        },
        {
            "staging_criteria": "Ewing Sarcoma: Metastatic",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Metastatic disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "VDC/IE chemotherapy + local control of metastases",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "FET-ETS fusions",
                            "status": "Present",
                            "testing_guidance": "Confirm via FISH/RT-PCR for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level III B"
                }
            ]
        },
        {
            "staging_criteria": "Ewing Sarcoma: Relapsed",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Recurrent/refractory disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Topotecan/cyclophosphamide, high-dose ifosfamide, or irinotecan/temozolomide",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "FET-ETS fusions",
                            "status": "Present",
                            "testing_guidance": "Confirm via FISH/RT-PCR for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level III B"
                }
            ]
        },
        {
            "staging_criteria": "Chondrosarcoma: Central Conventional",
            "risk_group": "Grade I (Atypical Cartilaginous)",
            "treatment_plans": [
                {
                    "clinical_context": "Low-grade central chondrosarcoma",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Curettage ± adjuvant therapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV B"
                }
            ]
        },
        {
            "staging_criteria": "Chondrosarcoma: Central Conventional",
            "risk_group": "Grade II/III",
            "treatment_plans": [
                {
                    "clinical_context": "High-grade or axial tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Wide-margin surgery",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV B"
                }
            ]
        },
        {
            "staging_criteria": "Chondrosarcoma: Mesenchymal/Dedifferentiated",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Aggressive subtypes",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Neoadjuvant/adjuvant anthracycline/alkylator-based chemotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV C"
                },
                {
                    "clinical_context": "Unresectable/metastatic disease",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pazopanib (ORR 31%)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level II"
                }
            ]
        },
        {
            "staging_criteria": "Chordoma: Resectable",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Primary resectable chordoma",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "En bloc R0/R1 resection + adjuvant radiotherapy (≥74 Gy; particle therapy preferred)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "Brachyury",
                            "status": "Nuclear expression",
                            "testing_guidance": "Immunohistochemistry for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level II B"
                }
            ]
        },
        {
            "staging_criteria": "Chordoma: Unresectable",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Skull base or unresectable tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Definitive high-dose radiotherapy (protons/carbon ions)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "Brachyury",
                            "status": "Nuclear expression",
                            "testing_guidance": "Immunohistochemistry for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level III B"
                }
            ]
        },
        {
            "staging_criteria": "Giant Cell Tumor of Bone: Resectable",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Primary resectable GCTB",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Curettage or en bloc excision",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "H3F3A",
                            "status": "Mutation (G34W)",
                            "testing_guidance": "G34W immunohistochemistry for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level IV A"
                }
            ]
        },
        {
            "staging_criteria": "Giant Cell Tumor of Bone: Unresectable/Metastatic",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Advanced GCTB",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Denosumab therapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "H3F3A",
                            "status": "Mutation (G34W)",
                            "testing_guidance": "G34W immunohistochemistry for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level III A"
                },
                {
                    "clinical_context": "Complex cases requiring downstaging",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Preoperative denosumab",
                    "treatment_line": "Neoadjuvant",
                    "biomarker_requirements": [
                        {
                            "name": "H3F3A",
                            "status": "Mutation (G34W)",
                            "testing_guidance": "G34W immunohistochemistry for diagnosis"
                        }
                    ],
                    "esmo_evidence_level": "Level II C"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Biomarkers are primarily diagnostic for specific sarcoma subtypes (e.g., FET-ETS fusions confirm Ewing sarcoma, brachyury for chordoma, H3F3A mutations for GCTB). IDH1/IDH2 mutations in chondrosarcoma aid subtyping but lack therapeutic implications. FET-ETS fusion types have lost prognostic significance in modern treatment protocols."
    }
}